Invention Grant
- Patent Title: High throughput arrhythmia risk assessment using multilead residua signals
-
Application No.: US14734966Application Date: 2015-06-09
-
Publication No.: US10022060B2Publication Date: 2018-07-17
- Inventor: Bruce D. Nearing , Richard L. Verrier
- Applicant: BETH ISRAEL DEACONESS MEDICAL CENTER, INC.
- Applicant Address: US MA Boston
- Assignee: Beth Israel Deaconess Medical Center, Inc.
- Current Assignee: Beth Israel Deaconess Medical Center, Inc.
- Current Assignee Address: US MA Boston
- Agency: Sterne, Kessler, Goldstein & Fox P.L.L.C.
- Main IPC: A61B5/04
- IPC: A61B5/04 ; A61B5/0456 ; A61B5/00 ; A61B5/0452

Abstract:
A method and system for high-throughput prediction of the onset of heart arrhythmias observes trends in abnormal or pathologic morphology of the electrocardiogram (ECG). A first set of ECG signals is monitored from a patient. A baseline measurement is generated from the monitored first set of ECG signals to contain nonpathologic ECG morphologies in each lead. A second set of ECG signals is monitored from the patient and a second baseline measurement is generated from the second set of ECG signals. A residuum signal is generated for each lead based on the baseline measurement and the second baseline measurement. The residuum signals are averaged across the leads. R-wave heterogeneity, T-wave heterogeneity, P-wave heterogeneity, or ST-segment heterogeneity or other indicators of arrhythmia risk or myocardial ischemia are quantified based on the generated residuum signals and the averaged residuum signal.
Public/Granted literature
- US20150272462A1 High Throughput Arrhythmia Risk Assessment Using Multilead Residua Signals Public/Granted day:2015-10-01
Information query